Serotonergic psychedelics, including psilocybin, show early promise for treating diverse neuropsychiatric disorders, but their therapeutic mechanisms are unclear. In a nonrandomized, single-arm pilot trial1 that enrolled people with Parkinson disease (PD) and mood dysfunction, psilocybin therapy was associated with improvements in depression as well as motor function. Elevated inflammation and mitochondrial stress are common in PD and may contribute to both mood and motor symptoms.2 Preclinical studies3,4 indicate that serotonergic psychedelics reduce inflammation and mitochondrial stress, suggesting potential mechanisms underlying clinical benefits. Prior studies4 have examined immunomodulatory effects of psychedelics in humans with mixed results but, to our knowledge, none have included people with PD or any other neurodegenerative disease. Further, to our knowledge, no published psychedelic study has measured mitochondrial markers in humans. In this analysis, we examined whether psilocybin administration was associated with changes in systemic markers of (1) inflammation and (2) mitochondrial stress in a sample of people with PD and mood dysfunction.